Aprea Therapeutics Inc. (NASDAQ:APRE) finished Wednesday with an addition of $0.07 to close at $5.58, an upside of 1.27 percent. An average of 1,750,600 shares of common stock have been traded in the last five days. There was a gain of $0.57 in the past week. The last 20 days have seen an average of 3,057,800 shares traded, while the 50-day average volume stands at 1,610,124.
APRE stock has increased by 23.45% in the last month. The company shares reached their 1-month lowest point of $4.32 on 09/23/21. With the stock rallying to its 52-week high on 02/11/21, shares of the company touched a low of $3.17 and a high of $30.99 in 52 weeks. In spite of this, the price is down -82.00% from the 52-week high.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
13 days have passed since Aprea Therapeutics Inc. (APRE) last reported insider trading activity. Korbel Gregory Alan, who is SVP, Chief Business Officer, most recently acquired $27,500 shares at $4.89 per share on Oct 01. In this transaction, the insider spent $134,475. SVP, Chief Scientific Officer, Abrahmsen Lars B., disposed of 50,000 shares at a price of $4.89 on Oct 01. The insider now owns more than $244,500 worth of shares. Prior to that, SVP, Chief Scientific Officer Abrahmsen Lars B. went on to Sale 25,000 shares at $4.97 each on Sep 20. An amount of $124,250 was transacted.
Aprea Therapeutics Inc. (APRE) has a trailing price-to-earnings (P/E) ratio of 34.65 for the broader industry and 32.30 for the sector. Other valuation ratios to consider include the price-to-book (PB) ratio at 1.94.
The quick ratio of Aprea Therapeutics Inc. for the three months ended June 29 was 6.70, and the current ratio was 6.70, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.00 and a total debt to equity ratio of 0.00 for the quarter ending June 29. Its gross profit as reported stood at -$0.22 million compared to revenue of $52.81 million.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Aprea Therapeutics Inc.’s return on assets was -54.80%. For the broader industry, ROE averaged -68.79 over the past year.
The analyst consensus anticipated Aprea Therapeutics Inc.’s latest quarter earnings to come in at -$0.47 per share, but it turned out to be -$0.48, a -2.10% surprise. For the quarter, EBITDA amounted to -$9.94 million. Shareholders own equity worth $21.19 million.
From a technical analysis perspective, let’s take a brief look at Aprea Therapeutics Inc. (APRE) price momentum. RSI 9-day as of the close on 13 October was 71.38%, suggesting the stock is Overbought, with historical volatility in this time frame at 48.91%.
As of today, APRE’s price is $5.42 +11.38% or $0.57 from its 5-day moving average. APRE is currently trading +20.26% higher than its 20-day SMA and +31.60% higher than its 100-day SMA. However, the stock’s current price level is +31.29% above the SMA50 and +1.45% above the SMA200.
The stochastic %K and %D were 88.74% and 83.67%, respectively, and the average true range (ATR) was 0.40. With the 14-day stochastic at 92.86% and the average true range at 0.39, the RSI (14) stands at 67.11%. The stock has reached 0.25 on the 9-day MACD Oscillator while the 14-day reading was at 0.38.
Robert W. Baird downgraded Aprea Therapeutics Inc. (NASDAQ: APRE) to a a Neutral rating in its most recent analyst report. Previously, the stock was rated as a an Outperform.The consensus rating for Aprea Therapeutics Inc. (APRE) among analysts is Underweight. According to current brokerage recommendations, 2 brokerage firms advise that investors sell APRE, while 3 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 0 others rate it as a “buy”.
What is APRE’s price target for the next 12 months?
Analysts predict a range of price targets between $3.00 and $5.00, with a median target of $4.00. Taking a look at these predictions, the average price target given by analysts for Aprea Therapeutics Inc. (APRE) stock is $4.00.